Navigation Links
Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
Date:12/4/2010

SOUTH SAN FRANCISCO, Calif., Dec. 4, 2010 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Poster Presentation Details

Specific Inhibition of Syk Suppresses Leukocyte Immune Function and Alleviates Inflammation In Rodent Models of Rheumatoid Arthritis

  • Presenter: Greg Coffey, Ph.D., Portola Pharmaceuticals
  • Poster Session: Lymphocytes, Lymphocyte Activation and Immunodeficiency, Including HIV and Other Infections: Poster I
  • Date: Saturday, December 4, 5:30 - 7:30 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board I-707

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity in Primary CLL Cells and is Synergistic with Fludarabine at Low Concentrations

  • Presenter: Stephen Spurgeon, M.D., Oregon Health & Science University Knight Cancer Institute
  • Poster Session: Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster I
  • Date: Sunday, December 5, 6:00 - 8:00 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board II-719

Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia

  • Presenter: Jan Burger, M.D., Ph.D., MD Anderson Cancer Center
  • Poster Session: CLL - Biology and Pathophysiology, excluding Therapy: Poster III  
  • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board III-383

Sub-Optimal Inhibition of Thrombus Formation by Aspirin (as measured by RTTP analysis) in Primary Thrombocythemia

  • Presenter: Gillian Stephens, Ph.D., Portola Pharmaceuticals
  • Poster Session: Pathophysiology of Thrombosis: Poster II
  • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board III-997

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales. Betrixaban, its oral direct Factor Xa inhibitor, is licensed to Merck & Co., Inc., and elinogrel, its competitive, reversible direct-acting i.v. and oral P2Y12 ADP receptor antagonist, is licensed to Novartis Pharma AG. Both are Phase 2 product candidates that have best-in-class features to address the global multi-billion dollar hospital, specialty and chronic care antiplatelet and anticoagulant markets.

Portola's proprietary pipeline programs are focused on the discovery and development of PRT064445, a novel recombinant protein anticoagulant antidote, known as the Factor Xa inhibitor antidote, to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in the next decade;  PRT061103, a thromboxane receptor antagonist, which is targeted to address a significant unmet need as a potential aspirin alternative for patients intolerant to aspirin; and PRT062607, a novel, oral Syk-specific kinase inhibitor to treat chronic inflammatory diseases, including rheumatoid arthritis  and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.  It is a part of our broader program based on novel Syk and JAK inhibitors to treat additional inflammatory disease and oncology. For additional information, visit www.portola.com.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
2. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
3. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
4. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
5. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
6. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
7. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
8. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
9. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
10. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
11. Onyx Pharmaceuticals Announces December 2010 Investor Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ... santé diversifiée innovante, est ravie d,annoncer les excellents résultats ... la période précédente correspondante. Une présentation complète « Résultats et ... être consultée ici . Faits ... de 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de ...
(Date:2/24/2017)... 23, 2017  This report analyzes the worldwide markets ... Products: Intermediates, Analytical, and Others. The ... Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive analytics ... Europe , and Rest of World. Annual ... through 2022. Also, a six-year historic analysis is provided ...
(Date:2/24/2017)... , Feb. 23, 2017  The particle counters ... by 2021 from USD 275.9 million in 2016, ... the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... on pharmaceutical R&D, and growth in manufacturing industries ... market growth for particle counters. On the other ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert ... because it’s not if you will be attacked, but when.” However, he and many ... digital health care. , Improvements in auditing and monitoring have taken security in health ...
(Date:2/24/2017)... Viejo, CA (PRWEB) , ... February 24, 2017 , ... ... Final Cut Pro X . Users have total control over position, rotation, distortion, ... and more all within Final Cut Pro X. , With ProGlass Prism users are ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and ... this year. Dyer started as the Chairman of the Management Committee when IFN ... the corporation including the recruitment of investor/owners and development of the business plan. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle ... hosted their Military Wedding Giveaway, with the winning couple announced on Feb. 14, ... services generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
Breaking Medicine News(10 mins):